Paclitaxel-eluting balloon catheter - Cardionovum

Drug Profile

Paclitaxel-eluting balloon catheter - Cardionovum

Alternative Names: LegflowDCB; Paclitaxel-eluting coronary PTCA catheter - Cardionovum; PrimusDCB

Latest Information Update: 19 Oct 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardionovum
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Immunosuppressants; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis; Peripheral artery restenosis

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 24 Sep 2012 Efficacy and adverse events data from a clinical trial and pharmacodynamic data from a preclinical trial in Coronary artery restenosis released by Cardionovum
  • 31 Mar 2012 Launched for Peripheral artery restenosis in Europe (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top